Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16374243 | 0.90 | MEN1 (0.32) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL304728 | 0.79 | CA12 (0.48) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL10716993 | 0.78 | TSHR (0.39) | MAPTCA12CA1CA2CA9 | |
| SCHEMBL3186938 | 0.78 | — | — | |
| SCHEMBL25285799 | 0.77 | MEN1 (0.33) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL10244731 | 0.77 | — | — | |
| SCHEMBL6200197 | 0.77 | MEN1 (0.33) | MAPTMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL18154102 | 0.75 | HDAC1 (0.51) | MAPTALDH1A1POLBGAA | |
| SCHEMBL304950 | 0.75 | CA1 (0.52) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL22167852 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272825-A2 | MTORC MODULATORS AND USES THEREOF | Aeovian Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2021195599-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-11021492-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| WO-2020154447-A1 | MTORC MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-1070045-B1 | METHODS FOR THE PREPARATION OF AN N-BIS- 2-(1,2-DICARBOXY-ETHOXY)-ETHYL]AMINE DERIVATIVE AND PRODUCTS OF THE METHODS AND THEIR USES | KEMIRA CHEMICALS OY (FI) | 2004-02-18 | — | — | EP | disclosed |
| EP-1070045-A1 | METHODS FOR THE PREPARATION OF AN N-BIS- 2-(1,2-DICARBOXY-ETHOXY)-ETHYL]AMINE DERIVATIVE AND PRODUCTS OF THE METHODS AND THEIR USES | KEMIRA CHEMICALS OY (FI) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999046234-A1 | METHODS FOR THE PREPARATION OF AN N-BIS-[2-(1,2-DICARBOXY-ETHOXY)-ETHYL]AMINE DERIVATIVE AND PRODUCTS OF THE METHODS AND THEIR USES | KEMIRA CHEMICALS OY (FI) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210002300-A1 | MTORC MODULATORS AND USES THEREOF | MTOR, RICTOR, RPTOR | MAPT 3533/4885CA12 4858/4885CA1 4866/4885 |
| US-20090198052-A1 | METHOD FOR PREPARING OPTICALLY ACTIVE PIPERIDINE COMPOUNDS | SNCA, SYNJ1, KCNH2 | MAPT 1047/4885CA12 2453/4885CA1 1003/4885 |
| US-11021492-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | MAPT 3533/4885CA12 4858/4885CA1 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.